Skip to main content

CCL2 DNA vaccine to treat renal disease

Journal Article


Abstract


  • CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.

Authors


  •   Watson, Debbie
  •   Zheng, Guoping (external author)
  •   Wu, Huiling (external author)
  •   Wang, Yuan-Min (external author)
  •   Wang, Yiping (external author)
  •   Harris, David C. (external author)
  •   Alexander, Stephen I. (external author)

Publication Date


  • 2009

Citation


  • Watson, D., Zheng, G., Wu, H., Wang, Y., Wang, Y., Harris, D. C. H. & Alexander, S. I. (2009). CCL2 DNA vaccine to treat renal disease. The International Journal of Biochemistry and Cell Biology, 41 (4), 729-732.

Scopus Eid


  • 2-s2.0-59849097571

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/1447

Has Global Citation Frequency


Number Of Pages


  • 3

Start Page


  • 729

End Page


  • 732

Volume


  • 41

Issue


  • 4

Place Of Publication


  • United Kingdom

Abstract


  • CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.

Authors


  •   Watson, Debbie
  •   Zheng, Guoping (external author)
  •   Wu, Huiling (external author)
  •   Wang, Yuan-Min (external author)
  •   Wang, Yiping (external author)
  •   Harris, David C. (external author)
  •   Alexander, Stephen I. (external author)

Publication Date


  • 2009

Citation


  • Watson, D., Zheng, G., Wu, H., Wang, Y., Wang, Y., Harris, D. C. H. & Alexander, S. I. (2009). CCL2 DNA vaccine to treat renal disease. The International Journal of Biochemistry and Cell Biology, 41 (4), 729-732.

Scopus Eid


  • 2-s2.0-59849097571

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/1447

Has Global Citation Frequency


Number Of Pages


  • 3

Start Page


  • 729

End Page


  • 732

Volume


  • 41

Issue


  • 4

Place Of Publication


  • United Kingdom